SWECARNET was established in 2019 by the SDP5 Swelife-ATMP project of the same name. Coordinated by the Centre for Cell therapy and Allogeneic Stem cell Transplantation (CAST) at Karolinska University Hospital, the network brings together those in Sweden developing, implementing or treating patients with Chimeric antigen receptor T (CAR T) cells. [Wikipedia]
Expected results and effects
The collaboration in this network will facilitate the translation of advanced therapies into clinical use and create an arena for innovation within academia and healthcare to be generated in, and with help from industry to reach patients. SWECARNET is expected to be at the forefront of the field both nationally and internationally and serve as a workhorse for solving challenges around the implementation of advanced therapies. SWECARNET will act as a catalyst to increase the number of clinical trials for CAR T and other advanced therapy medicinal products in Sweden.
Planned approach and implementation
All members in SWECARNET will be involved and work together on 8 different work packages with an assigned project leader. SWECARNET arranges quarterly meetings where we work together, follow up and report the progress made in the various work packages. SWECARNET is led by Professor Stephan Mielke, Karolinska Institutet and Karolinska Universitetssjukhuset together with Professor Gunilla Enblad, Uppsala Universitet and Akademiska Sjukhuset.
SWECARNET has and will continue to have a wide impact within the field of personalized medicine, creating new markets for industry, contributing to sustainable healthcare, better treatments and improved patient quality of life and a healthier and more productive society.
SWECARNET will act as a catalyst to increase the number of clinical trials for CAR T and other gene-modified effector T cells in Sweden
SWECARNET will facilitate; translating academic science into clinically usable technologies, increased speed of innovation cycles, and development of new life- saving therapies.
SWECARNET facilitates implementation and system feedback in the area of CAR T and other gene-modified effector T cells by connecting key stakeholders in the innovation ecosystem and allowing them to share results via regular, targeted events
SWECARNET contributes to saving lives, restoring QoL, cure cancers and enabling patients to return to work/normal life.
SWECARNET will serve as the workhorse (arbetshäst) for ATMPs in Sweden, giving Sweden an internationally leading role in ATMPs, Cancer Care and other indication areas.
SWECARNET will be at the forefront of the field, solving national challenges regarding the implementation of advanced therapy medicinal products together with other stakeholders and projects.